Zymeworks (ZYME) Common Equity (2021 - 2026)

Zymeworks has disclosed Common Equity across 6 years of filings, most recently posting $163.6 million for Q1 2026.

• Common Equity for Q1 2026 came in at $163.6 million, down 49.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $163.6 million (down 49.66% YoY), and the FY2025 annual result was $268.5 million, down 20.74% from the prior year.
• Common Equity came in at $163.6 million for Q1 2026 at Zymeworks, down from $268.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $493.0 million in Q4 2022 to a low of $163.6 million in Q1 2026.
• The 5-year median for Common Equity is $338.8 million (2024), against an average of $350.0 million.
• Across the five-year window, Common Equity surged 136.06% in 2023 and tumbled 49.66% in 2026, its largest moves.
• Zymeworks' Common Equity stood at $493.0 million in 2022, then decreased by 5.71% to $464.8 million in 2023, then slipped by 27.12% to $338.8 million in 2024, then decreased by 20.74% to $268.5 million in 2025, then sank by 39.07% to $163.6 million in 2026.
• The last three Common Equity figures came in at $163.6 million (Q1 2026), $268.5 million (Q4 2025), and $320.1 million (Q3 2025), per Business Quant data.